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Abstract
We recently reported that the Ins2Akita mouse is a good model for late-onset diabetic retinopathy. 
Here, we investigated the effect of miR200-b, a potential anti-angiogenic factor, on VEGF receptor 
2 (VEGFR-2) expression and to determine the underlying angiogenic response in mouse 
endothelial cells, and in retinas from aged Ins2Akita mice. MiR200-b and its native flanking 
sequences were amplified and cloned into a pCAG-eGFP vector directed by the ubiquitous CAG 
promoter (namely pCAG-miR200-b-IRES-eGFP). The plasmid was compacted by CK30PEG10K 
into DNA nanoparticles (NPs) for in vivo delivery. Murine endothelial cell line, SVEC4-10, was 
first transfected with the plasmid. The mRNA levels of VEGF and VEGFR-2 were quantified by 
qRT-PCR and showed significant reduction in message expression compared with lipofectamine-
transfected cells. Transfection of miR200-b suppressed the migration of SVEC4-10 cells. There 
was a significant inverse correlation between the level of expression of miR200-b and VEGFR-2. 
Intravitreal injection of miR200-b DNA NPs significantly reduced protein levels of VEGFR-2 as 
revealed by western blot and markedly suppressed angiogenesis as evaluated by fundus imaging in 
aged Ins2Akita mice even after 3 months of post-injection. These findings suggest that NP-
mediated miR200-b delivery has negatively regulated VEGFR-2 expression in vivo.
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1. Introduction
Diabetic retinopathy (DR) is a highly specific retinal microvascular complication of diabetic 
patients worldwide and continues to be the leading cause of blindness among working age 
Americans [1–3]. In diabetes, hyperglycemia is a key stimulating factor for severe metabolic 
changes in vascular endothelial (EC) cells and results in vascular injuries [3,4]. The 
compromised stability of EC cells recruits and activates different transcription factors and 
alters the expression of different growth factors, including vascular endothelial growth factor 
(VEGF), which in turn deteriorates the structure and function of the retina [5]. Recent 
studies have explored elevated VEGF levels in the intraocular space of patients with DR, 
which has been hypothesized as the primary pathogenic factor in the angiogenesis seen in 
DR [5–9]. VEGF is a heparin binding homodimeric glycoprotein that specifically binds to 
tyrosine kinase receptors (TKRs), VEGFR-1 (Flt 1, fms-like tyrosine kinase 1), VEGFR-2 
(Flk-1, fetal liver kinase), or 1/KDR (kinase insert domain receptor) on the vascular EC 
surface [10]. These receptors direct different physiological (e.g. embryonic development) 
and pathological angiogenesis (e.g. DR, tumor progression, inflammation etc.). VEGFR-1 is 
expressed both in normal and diabetic retina and is responsible for organization of normal 
vascular channels. Studies show that the Flt-1−/− mice die in utero between 8.5 and 9.5 
embryonic days due to disorganization of blood vessels [11,12]. VEGFR-2 is responsible for 
migration, proliferation and survival as well as stimulation of angiogenesis and vascular 
permeability at the late stage of DR (i.e. proliferative DR) [10]. Therefore, modulation of 
increased VEGF receptors and inhibition of their function in the eye may become a logical 
method of controlling normal vascular homeostasis, as well as a possible treatment for DR.
MicroRNAs (miRNAs) are a class of naturally occurring small and non-coding RNA 
molecules [13,14]. miRNA has been recognized as a key component in regulating cell 
differentiation, apoptosis, cell proliferation and organ development. More than 60% of 
human proteins are regulated by miRNAs [14]. It silences gene expression at the post-
transcriptional level by base pairing with perfect or nearly perfect complementary 3′-
untranslated region (3′-UTR) of the target mRNA that results in a cleavage of mRNA and 
translational repression occurs [14]. Therefore, it is hypothesized that dysregulation in the 
biogenesis and function of miRNAs may be involved in the pathogenesis of various human 
diseases, including DR. The miR200 family is established as an anti-angiogenic factor that 
can inhibit the growth of new blood vessels by down regulating VEGF [15,16]. Among all of 
the miR200 members, miR200-b is one of the most potent endogenous inhibitors involved in 
anti-angiogenesis and also is a well-studied therapeutic target as a tumor suppressor [16]. 
Although miR200-b has been successful in inhibiting VEGF gene expression in vitro and in 
in vivo models [15], its therapeutic delivery into the retina has not been extensively 
evaluated. Recently, the delivery of miR200-b was carried out using lipofectamine and with 
a dose of 1.4 μg/week (duration of 4 weeks) in streptozotocin (STZ)-induced diabetic rats 
which demonstrated that miR200-b has a negative role in regulating VEGF induced DR [15].
Gene therapy is a promising strategy for treating a number of disorders. This could be 
especially beneficial for patients for whom standard options won’t work or are not available. 
Although viral vector based gene delivery has been proven to be robust in gene delivery, it 
has several inherent concerns [17,18]. We have previously shown the effectiveness of 
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CK30PEG10K compacted DNA NPs in efficiently transfect retinal tissues [18–21]. The 
expression of the therapeutic gene can result in long-term expression, rescue retina cells, and 
improve phenotypes in different neurodegenerative models (ABCA4−/−, RPE65−/−, Rds+/−, 
Rho−/− mice) [20,22–26]. Earlier research on these DNA NPs determined that an acetate 
counterion to lysine amines could compact plasmid DNA into a rod shape with an 8–11 nm 
diameter and a length proportional to the plasmid size [27,28]. These NPs have a tolerable 
safety profile with a lack of immunogenicity in the retina after delivery through intravitreal 
and subretinal routes, including multiple dosing [21,25,29]. Our strategy here is to 
intravitreally deliver CK30PEG10k compacted therapeutic miR200-b plasmid DNA to 6 
month old diabetic Ins2Akita mice and evaluate its therapeutic role against VEGF-mediated 
angiogenesis at 3 months post injection (PI-3 m). We show that a single NP-mediated 
miR200-b dose negatively regulates VEGFR-2 expression in the type 1 diabetic Ins2Akita 
mouse model of DR and demonstrate phenotypic improvements at 3 months post intravitreal 
injection. This approach may lead to an effective anti-angiogenic therapy for DR.
2. Materials and methods
2.1. Animal husbandry
Ins2Akita heterozygous male and female breeder pairs with C57BL/6 background were 
kindly provided by Dr. Jason Kim at the University of Massachusetts Medical School. All 
the breeding colonies under investigation were in the C57BL/6 background and maintained 
in cyclic light (12 L:12 D) condition with water and food. After the onset of diabetes, freshly 
prepared cages were provided to all of the mice due to diabetes associated polyuria. All of 
the experiments, under our investigation were approved by University of Oklahoma Health 
Science Center Institutional Animal Care and Use Committee (IACUC), and followed to the 
National Institute of Health Guide for the Care and Use of Laboratory Animals and the 
Association for Research in Vision and Ophthalmology resolution on the Use of Animals in 
Research (Rockville, MD, USA). Homozygote Ins2Akita mice are postnatal lethal (rarely 
survive beyond 12 weeks of age). The diabetic phenotype is more severe and progressive in 
heterozygous males than in heterozygous females. Thus, only Akita heterozygous male mice 
were used in this study. Aged matched WT littermates were used as controls.
2.2. NP formulation and characterization
DNA NPs were synthesized as mentioned earlier [27,30]. Briefly, a 30-mer L-lysine 
polypeptide with N-terminal cysteine residue (CK30) was conjugated with 10 kDa 
polyethylene glycol maleimide (PEG-maleimide, 10 kDa) via thiol-maleimide 
bioconjugation. After counterion exchange with acetate, CK30-PEG10k-acetate was 
generated and used to condense the pCAG-miR200-b-IRES-eGFP plasmid DNA (Fig. S1) as 
unimolecularly compacted DNA NPs at N/P ratio of 2 using charge neutralization between 
peptide (positive charges from ammonium groups) and DNA (negative charges from 
phosphates). The NPs were taken in saline (endotoxin free) and concentrated to 4.3 μg DNA/
μl.
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2.3. Cell culture
The mouse EC line SVEC4-10 was purchased from ATCC, USA. The cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and 1× of antibiotics and antimycotics mixture (AA, 100× stock) to each liter of 
medium at pH 7.4. The cells were incubated at 37 °C and 5% CO2 throughout the study.
2.4. Wound healing assay
The cells were grown at 50–60% confluence for 12–18 h before transfection. The EC cells 
were transfected with pCAG-miR200-b-IRES-eGFP plasmid DNA (2 μg) using transfecting 
agent (lipofectamin 2000, Invitrogen). Untreated cells were taken as negative control. The 
cells were incubated at 37 °C until attaining a monolayer with 100% confluence. p200 pipet 
tips were used to create a scratch through the cell monolayer. Fresh media was added to the 
plate and incubated again at 37 °C. After 24 h, phase-contrast images were acquired to track 
cell migration and wound closure phenotype.
2.5. Tube formation assay
SVEC4-10 cells were transfected with lipofectamine 2000 and pCAG-miR200-b plasmid 
DNA complexes in 6 well plates. After 24 h of transfection, 1 × 104 cells were transferred in 
100 μl of growth factor reduced matrigel (356230, BD Bioscience) to pre-coated 12 well 
plates along with untreated negative control cells. Tube formation was visualized and 
demonstrated after 0 and 24 h of this seeding.
2.6. Intravitreal injections
Intravitreal injections were performed as previously described [31] in postnatal (P) 6 month 
old Ins2Akita and age matched WT controls. Animals were first anesthetized by 
intramuscular injection of 85 mg/kg ketamine and 14 mg/kg xylazine (Butler Schein Animal 
Health, Dublin, OH). The cornea was then carefully penetrated using a 30-gauge needle to 
make a hole. A 35-gauge needle attached to a 10 μl Nanofil syringe (World Precision 
Instruments, Sarasota, FL, USA) was then inserted through the puncture site with 
visualization aided by use of an operating microscope (Carl Zeiss Surgical, Incorporated, 
Thornwood, NY, USA) to deliver pCAG-miR200-b NPs (2.0 μl, 4.3 μg/μl) or pCAG-IRES-
GFP (mock, 2 μl 4.3 μg/μl in saline) into the vitreal cavity. A drop of triple antibiotic 
(Equate, Wal-Mart, Bentonville, AR, USA) ointment was applied on the corneal surface 
after this injection. Mice were placed on a 37 °C bed until fully awake. All of the in vivo 
analyses were carried out at PI-3 m and 3–5 mice per group were taken for injections.
2.7. Fundus photography (fluorescein angiography)
Fundus photographs were acquired following our earlier method with Micron III (Phoenix 
Research laboratories, Pleasanton, CA) imaging system [32,33]. Animals were first 
anesthetized by intramuscular injection of 85 mg/kg ketamine and 14 mg/kg xylazine 
(Butler Schein Animal Health, Dublin, OH). 100 μl of 1% fluorescein sodium (Sigma-
Aldrich, St. Louis, MO) solution was then injected intraperitoneally. 1% Cyclogyl 
(cyclopentolate hydrochloride solution) was used to dilate the eyes and a drop of 2.5% 
methylcellulose (both from Pharmaceutical Systems, Inc., Tulsa, OK) was used on the 
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corneal surface. Photographs were acquired using white light or a filter with excitation at 
∼482 nm and emission at ∼536 nm using commercially available software (StreamPix 
Software; Phoenix Research Laboratories).
2.8. Western blotting
Western blotting was performed using standard protocols [19,20]. Retina samples were 
separated from corneas and lenses followed by homogenization and lysis in extraction buffer 
(PBS pH 7.0 containing 1% triton-× 100, 5 mM EDTA, 5 mg/ml n-ethylmaleimide, and a 
standard protease inhibitor cocktail) by short sonication on ice. After the extraction, samples 
were centrifuged at 4 °C to precipitate insoluble materials and supernatants were collected in 
fresh tubes on ice. Concentrations of isolated proteins were measured by the Bio-Rad 
protein assay kit (calorimetric protein assay, Bradford assay, Bio-Rad, Hercules, CA). The 
anti-VEGF (ab46154) and Flk-1 (C-1158: sc-504) antibodies were purchased from Abcam 
and Santa Cruz, respectively. The protein samples were always kept on ice for subsequent 
analysis and were stored at −80 °C. Equal amounts of total protein were run and separated 
by 10% SDS-PAGE followed by transfer to PVDF membrane (Millipore, Inc., Billerica, 
MA). Membranes were blocked with 5% non-fat milk in TBST and then incubated with 
primary antibody (1:1000) overnight at 4 °C. Membranes were washed with 1×TBST (3 
times; 10 min each) and then treated with HRP conjugated goat anti-rabbit IgG antibody 
(sc-2030, Santa Cruz) at 1∶25,000 and incubated for 2 h at room temperature, and washed as 
earlier followed by visualization using SuperSignal West Dura Extended Duration Substrate 
(Thermo Scientific, Rockford, IL) according to the manufacturer’s guidelines. Blots were 
imaged by ChemiDoc™ MP imaging system (Bio-rad) and densitometric analyses were 
performed using Image Lab software v4.1 (Bio-rad). The pixel densities in each band were 
normalized to the amount of β-actin (housekeeping) in that lane.
2.9. Quantitative real-time PCR (qRT-PCR)
qRT-PCR was carried out following our earlier protocols [19,20, 32–34]. Total RNAs were 
isolated from each retinal samples using Trizol reagent (Life Technologies, Grand Island, 
NY, USA) following manufacturer’s instructions. RNase-free DNase I (Promega, USA) was 
used to remove any DNA contamination according to manufacturer’s protocol. cDNAs were 
prepared from total RNA samples using reverse transcription by Oligo-dT primer along with 
Supercript III reverse tanscriptase (RT) (Life Technology, USA). In all of our experiments, 
no RT (without reverse transcriptase) was included as negative control for each sample. qRT-
PCR of the samples were carried out using SYBR green and the CFX96 real-time cycler 
(Bio-Rad, Hercules, CA, USA). Each sample was measured in triplicate and normalized to 
housekeeping gene β-actin. Relative gene expression was analyzed using the ΔcT method 
(i.e. ΔcT = gene cT- β actin cT). Each treatment was determined using three to five eyes and 
data are shown as means ± SE. The primers used were: forward VEGF-A: 5′-
AGCACAGCAGATGTGAATGC-3′, reverse VEGF-A: 5′-
AATGCTTTCTCCGCTCTGAA-3′, forward VEGFR-2: 5′-
TAAGGGCATGGAGTTCTTGG-3′, reverse VEGFR-2: 5′-
CAGAGCAACACACCGAAAGA-3′, mouse actin forward: 5′-
TGTTACCAACTGGGACGACA-3′; mouse actin reverse: 5′-
CTTTTCACGGTTGGCCTTAG-3′.
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2.10. Electron microscopic (EM) analysis
EMs on ultrathin plastic sections along the nasal/temporal plane was performed using an 
electron microscope (100CX; JEOL, Tokyo, Japan) as described previously [20,32]. The 
eyes were initially fixed in 2%/2% paraformaldehyde/glutaraldehyde at room temperature 
and followed by the careful removal of the cornea and lens from each eye. The eyecups were 
post fixed in 1% OsO4 at room temperature. After staining, the eyes were rinsed with water 
and eyecups were embedded in Spurr’s resin (Ted Pella Incorporated, Redding, CA, USA) 
for sectioning. Semi thin (0.75 μm) sections were stained with 1% toluidine blue in 1% 
sodium borate. One to three animals per group were analyzed. Ultrathin electron microscopy 
sections cut along the superior-inferior plane were post stained with uranyl acetate and lead 
citrate and imaged at ×25,000 using a JEOL 100CX electron microscope.
3. Results
3.1. miR200-b down-regulates VEGF in vitro
VEGF expression in DR is the key factor to regulate angiogenesis. miR200-b acts as an anti-
angiogenic factor and is highly enriched in epithelial tissues. To elucidate the VEGF 
regulation by miR200-b, we first choose to test its effectiveness in an in vitro model (murine 
SVEC4-10), the primary cell target in DR. EC cells were transfected with pCAG-miR200-b-
IRES-eGFP plasmid DNA complexed with lipofectamine 2000. Native eGFP fluorescence 
was assessed in transfected cells and compared with the untreated control (Fig. 1A). eGFP 
expression reflects the functional integrity of the plasmid DNA and the transfection ability 
of the lipofectamine mediated DNA complex.
In a parallel study, VEGF mRNA levels were evaluated in miR200-b transfected EC cells. 
We observed that the relative mRNA levels of endogenous VEGF-A (Fig. 1B) and 
VEGFR-2 (Fig. 1C) were significantly down-regulated in miR200-b transfected cells as 
measured by semi quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
when compared to mock (lipofectamine only) treated controls. On the other hand, the 
untreated (endogenous) and mock control groups showed no alteration in VEGF-A or 
VEGFR2 levels (Fig. 1B and C). All together these results define the anti-VEGF activity of 
miR200-b plasmid in EC cells.
3.2. miR200-b delayed wound repair
The wound-healing assay provides a valuable in vitro tool for validating the collective 
processes of cell migration, motility, and proliferation. To examine whether treatment of 
miR200-b exerts anti-angiogenic effects in wound healing in EC cells, we performed wound 
closure assays in SVEC EC cells. Untreated SVEC cells migrate faster toward the scratch 
than the miR200-b treated cells (Fig. 1D). Delivery of miR200-b significantly inhibited 
wound repair in SVEC cells within a day (24 h) after treatment with the pDNA (Fig. 1E). 
The angiogenesis can also be characterized by cell differentiation into capillaries and an in 
vitro tube formation or capillary formation (three dimensional structures) assay is well-
established for predicting in vivo anti-angiogenesis. To analyze if miR200b could inhibit 
tubular network formation, SVEC cells were transfected with pCAG-miR200-b 
lipofectamine 2000 complexes. As shown in Fig. 2F, pCAG-miR200-b clearly inhibited 
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tube-like structures compared to the untreated control. Taken together, these results 
demonstrate that miR200-b has a negative effect on the angiogenic activity of EC cells.
3.3. miR200-b NPs prevent DR-associated vascular changes
Vascular abnormalities are sensitive indicators of DR. To examine whether intravitreal 
delivery of miR200-b DNA NPs could prevent retinal neovascularization and 
microaneurysms, we performed noninvasive fluorescence fundus imaging on Ins2Akita mice 
at PI-3 m. Mock injected and age matched WT mice were used as controls. The results of 
the imaging clearly indicate that treatment with miR200-b DNA NPs can prevent vascular 
changes, including neovascularization and vascular leakage, compared with the mock 
injected controls (Fig. 2 and Fig. S2). We used ImageJ software to quantitatively measure 
the vasculature area on fundus images of Ins2Akita mice. As shown in Fig. 3A and B, 
significant reduction in vasculature area is detected with pCAG-miR200-b NPs treated eyes 
when compared to age matched mock treated Akita. Consistent with the fluorescence 
angiography, recovery of the vascular area was comparable to values observed in age 
matchedWT. Thus NP-mediated reversal of retinal vascular damage could have a significant 
impact on the improvement of DR.
3.4. miR200-b NPs down-regulate retinal VEGF levels in aged Ins2Akita mice
To investigate the anti-angiogenic activity of the pCAG-miR200-b DNA NPs to VEGF-
directed angiogenesis, we measured VEGF A (Fig. 4A and B) and VEGFR-2 (Fig. 4A and 
C) expression in retinas isolated from P9m old Ins2Akita mice. Western blots (Fig. 4A) 
demonstrated that VEGFR-2 expression was significantly down-regulated by the NPs 
compared to the mock injected controls (Fig. 4A and C). The VEGFR-2 level shows 
comparable values as aged matched WT controls (Fig. 4C). Results from these in vivo 
experiments were consistent with our in vitro results (Fig. 1C). However, interestingly, our 
in vivo experiments showed that the miR200-b NP formulation may more directly target 
VEGFR-2 than that of VEGF-A (Fig. 4), which plays a crucial role in endothelial 
development through cell proliferation and migration in angiogenesis. This observation is in 
agreement with the previous report [35].
3.5. miR200-b NPs treatments lead to ultrastructural improvements on retinal capillaries
Pathologically, retinal capillary wall breakdown, basement membrane thickening and death 
of capillary pericytes are early signs of DR. Fig. 5A presents a cartoon diagram of a 
capillary blood vessel cross section in WT mice. To determine the effects of miR200-b DNA 
NPs on the capillary structure and pathogenesis of DR in Ins2Akita mice, we evaluated the 
ultrastructure of retinal capillaries in electron microscopic (EM) images taken from NP 
injected 9 month old Ins2Akita mice (PI-3 m). Age matched uninjected WT and mock 
injected Ins2Akita mice were used as controls (Fig. 5B and C). We show that the treatment 
with NPs improves pericyte coverage and decreases basement membrane thickness (Fig. 5D) 
compared to the mock treated Ins2Akita (Fig. 5C and Fig. S3) control at PI-3 m.
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4. Discussions
In the present study, we demonstrated for the first time the down-regulation of VEGFR-2 
receptor after a single intravitreal administration of miR200-b DNA NPs under the control of 
the ubiquitous CAG promoter after 3 months post injection. We have shown that NP 
mediated therapeutic intervention can target the VEGFR-2 receptor and controls 
pathological clinical phenotype of angiogenesis.
VEGFs are a family of isoforms that are generated by alternative splicing of VEGF mRNA 
[10]. VEGF is produced by retinal vascular and neuroglia cells (e.g. Müller cells) and is a 
growth factor for the exudative and proliferative angiogenesis in DR. Among the four VEGF 
isoforms as found in humans, VEGF-A isoform binds to two cell surface 
autophosphorylating receptor tyrosine kinases (RTKs), VEGFR-1 (Flt-1) and VEGFR-2 
(Flk-1/KDR) regulate the process of angiogenesis. VEGFR-2 is more potent than VEGFR-1 
in stimulating endothelial cells [36]. VEGF binds and dimerizes two VEGFR-2 monomers 
that leads to receptor autophophorylation of VEGFR-2 tyrosine domains. These 
phosphotyrosines recruit several adaptor proteins that finally directs a wide spectrum of 
cellular signaling cascades like proliferation, migration and differentiations in EC cells [37]. 
The anti-apoptotic effect of VEGF in human umbilical vein EC cells was demonstrated via 
activation of VEGFR-2 but not with VEGFR-1 [10,38]. Studies have shown that the 
suppression of VEGFR-2, the primary signal transducer for angiogenesis, can block the 
VEGF-VEGFR-2 signaling pathway and leads to the inhibition of intraocular vascular 
leakage and neovascularization [39]. Other small molecule angiogenic inhibitors target 
VEGFR-2 to inhibit tumor growth, metastasis, and angiogenesis [40,41]. Therefore, 
VEGFR-2 is an important receptor for VEGF and an important target for anti-angiogenic 
therapy by inhibiting retinal neovascularization.
Currently, laser surgery and panretinal photocoagulation (PRP) therapies are available for 
the treatment of DR and age related macular degeneration. Multiple scattering laser 
treatments temporary shrink abnormal blood vessels. Recently, the FDA has approved 
several drugs for the treatment of DR like Eylea (Aflibercept, made of a human antibody 
fragment), and Lucentis (Ranibizumab, a monoclonal antibody fragment) that targets VEGF 
and works as anti-VEGF therapy. These drugs require monthly injections into the vitreous in 
order to maintain long-term effects. In addition, these drugs neutralize VEGF ligands in the 
blood stream and prevent the dimerization of VEGFR-2 receptors that consequently inhibit 
neovascularization. Therefore, there is clear demand for alternative and effective therapies to 
manage, control and reverse the ocular neovascularization phenotype seen in DR. To this 
end, our strategy is to target new retinal blood vessel formation by delivering miR200-b NPs 
into EC cells to knock down the expression of VEGFR-2. We showed that DNA NP-
mediated miR200-b delivery can negatively regulate VEGFR-2 expression and inhibit 
intraocular pathological angiogenesis by inhibiting the VEGF-VEGFR-2 signaling pathway, 
with a safe and minimally invasive surgical procedure up to 3 months after a single 
intravitreal injection.
We have used EC cells for our initial investigation of miR200-b mediated down-regulation 
of VEGFR-2 in diabetes. We have chosen these cells, which are not a retinal cell line, 
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because they have been widely used as a model for studying EC abnormalities for other 
diseases such as neovascular proliferation in cancer [42]. The antiproliferative and vascular 
targeting consequences of the miR200-b plasmid DNA were validated in vitro in murine 
SVEC4-10 EC cells by a significant down regulation of cell proliferation, migration and 
tube formation. Studies have shown that the VEGFR-2 receptor directs the differentiation of 
EC cells into capillary tubes [39]. The potent activity of miR200-b in targeting VEGFR-2 to 
reduce retinal neovascularization was validated through a tube formation assay in vitro [15]. 
The EC migration, vacuolization and cell elongation in 3D gels was greatly inhibited by 
miR200-b treatment that directly reflects its VEGFR-2 targeting efficiency. VEGF ligand is 
needed to maintain the homeostasis of choriocapilaries, cones and ganglion cells in retina 
and consequently severe VEGF inhibition might result in structural disintegration and 
photoreceptor cell damage. Therefore, targeting and down regulation of VEGFR-2 is the key 
strategy of our current study by inhibiting neovascularization in a DR model.
Although chemical- and injury-induced models of retinal neovascularization exist, they are 
not able to mimic the chronic DR processes. The Ins2Akita mouse is a common diabetic 
model to study VEGF dependent neovascularization resulting from hyperglycemia. Ins2Akita 
possess a dominant point mutation in the gene encoding insulin-2 that leads to the 
misfolding of the insulin protein and established a monogenic model for studying non-
insulin-dependent diabetes mellitus (DM). Previously, we [32] and others [43–45] have 
shown that the Ins2Akita model presents increased retinal vascular permeability, apoptosis 
and produces early signs of DR. Our previous study indicated that Ins2Akita mice develop 
hyperglycemia-associated vasculopathies and acts as a relevant model for later-onset DR 
with early and some late disease symptoms. We demonstrated that this mouse model exhibits 
early and late chronic DR signs and may be a suitable model for testing the therapeutics that 
are designed to target DR.
Naked plasmid DNA is unable to efficiently overcome numerous biological barriers in the 
cytoplasm. NPs can protect DNA from enzymatic cleavage. CK30PEG10k based DNA 
nanocompaction has been well-documented in retinal gene therapies by us and other groups 
as well. The CK30PEG10k mediated DNA NP formulations have been reported to be 
internalized into cells via nucleolin receptors [46,47]. Nucleolin is a cell surface receptor in 
angiogenic EC cells [48] and shuttles between the nucleus, cytoplasm and cell surface. 
Studies have shown that anti-angiogenic endostatin was taken up by the cells and transported 
into the nuclei of EC via nucleolin receptor and subsequently prevented growth and 
angiogenesis [49,50]. Therefore, the miR200-b DNA NP might be internalized and shuttled 
to the nucleus of EC cells via nucleolin receptors, subsequently expresses miR200-b that 
consequently knocks down VEGFR-2 expression as shown by both messenger and protein 
analyses (Fig. 4) and prevents neovascularization as indicated by fundus imaging (Figs. 2 
and 3). Our in vivo results show that pCAG-miR200-b DNA NPs can prevent ocular 
neovascularization in the Ins2-Akita model via suppression of VEGFR-2 activation. Human 
diabetic retinas have a reduction in the mir200-b level [15] that supports our miR200-b NP-
mediated approach as a supplemental therapeutic for the treatment of DR to maintain 
vascular homeostasis in the diabetic retina. In this current study, we have demonstrated that 
miR200-b compacted DNA NPs injected via the intravitreal route might be a first line 
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therapeutic strategy for ocular neovascularization treatment and which may not need 
repetitive injections.
5. Conclusion
The development of nanotechnology has been growing in managing diabetes based on its 
success in other diseases like cancer [51]. Here we have shown that NP-mediated mir200-b 
delivery can protect the retina from retinal neovascularization by down regulating VEGFR-2 
expression. This study provides important evidence of targeting VEGFR-2 by mir200-b in a 
hyperglycemic model of DR and might open up a potential therapeutic alternative in the 
management of VEGF-mediated neovascularization in DR.
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Fig. 1. 
(A) In vitro transfection of pCAG-miR200-b-IRES-eGFP with lipofectamine 2000 (mock, 
top panel) and without lipofectamine (bottom panel) in SVEC cells. Left and right rows 
represent images taken in bright field (BF) and GFP channel, respectively. (B) Relative 
VEGF-A mRNA expression (n = 3). (C) Relative VEGFR-2 mRNA expression (n = 3). 
Quantitative analyses were analyzed by measuring mRNA expression relative to 
housekeeping beta actin. Significance was measured with one-way ANOVA analysis with 
Bonferroni multiple comparison test (B & C). Each value represents the mean (±SEM). (D) 
SVEC cells transfected with pCAG-miR200-b-IRSE-eGFP pDNA exhibited significant 
migration compared to the untreated control after creating the wounds (market by yellow 
margin). (E) Differences in the migrations of EC cells (i.e. wound healing) were statistically 
significant. The extent of wound closure was determined by measuring the wound area 
healed with miR200-b treatments compared with the initial wound area (n = 3, *P < 0.05). 
Untreated cells were taken as control under the same experimental condition. Significance 
was measured with t-test and each value represents the mean ± SEM. (F) The representative 
morphogenic responses of SVEC cells cultured onto 3D-matrigel after transfection with 
pDNA (right panel) and without treatment (left panel). Images were taken after 0 and 24 h of 
seeding onto matrigel. Images (A, D & F) were captured at 20× using Axioscope; Carl Zeiss 
Meditec, Jena, Germany.
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Fig. 2. 
Fluorescein angiography shows the inhibition of retinal neovascularization in male Ins2Akita 
animals treated at 9 months of age and assessed at 3 months post injection (PI-3 m) with 
miR200-b DNA NPs and compared with the age matched mock (pCAG-IRES-eGFP) 
injected positive control. Age matched and untreated wild type (WT) mice were taken as 
negative control. Top and bottom panels represent photographs from bright field and GFP 
channel.
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Fig. 3. 
(A–B) Vascular area was determined by considering the area occupied by the green 
fluorescence and quantified by NIH Image J software for each separate eye. Values are 
presented as mean ± SEM and are significantly different (*P < 0.05). Significance was 
measured by one-way ANOVA (n = 3). The mock, in this study, represents the injection of 
the pCAG-IRES-eGFP in endotoxin free saline.
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Fig. 4. 
(A) Western blot analysis of VEGFR-2 and VEGF-A proteins. miR200-b DNA NP injected 
eyes showed significant amounts of VEGFR-2 down-regulation. (B–C) Relative expression 
of VEGF-A and VEGFR-2 proteins from untreated WT, mock (pCAG-IRES-eGFP) treated 
Ins2Akita and NP injected Ins2Akita mice at 3 months post injections. All mice were age 
matched and injected at 6 months of age. Values are presented as mean ± SE and are 
significantly different (***P < 0.001). Significance was measured by one-way ANOVA (n = 
4).
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Fig. 5. 
(A) A cartoon diagram of a transverse section of retinal capillary structure. Representative 
transmission electron micrographs (EM) of retinal capillaries from the outer plexiform layer 
of age matched (B) WT (untreated), and (C) Ins2Akita (pCAG-IRES-eGFP mock injected). 
There is a loss of pericytes found in the mock treated Ins2Akita capillary structure, and (D) 
DNA NP-miR200-b injected retinas. BM: basement membrane, EC: endothelial cell, CL: 
capillary lumen, P: pericyte (Note: pericytes share their basement membrane with retinal EC 
cells). Scale bar = 500 nm.
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